Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain

BACKGROUND: Although the benefit of first-line epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKIs) over chemotherapy has been demonstrated in several clinical trials, data from clinical practice is lacking and the optimal EGFR TKI to be used remains unclear. This study aims to...

Descripción completa

Detalles Bibliográficos
Autores principales: Arriola, Edurne, García Gómez, Ramón, Diz, Pilar, Majem, Margarita, Martínez Aguillo, Maite, Valdivia, Javier, Paredes, Alfredo, Sánchez-Torres, José Miguel, Peralta Muñoz, Sergio, Barneto, Isidoro, Gutierrez, Vanesa, Andrade Santiago, Jesús Manuel, Aparisi, Francisco, Isla, Dolores, Ponce, Santiago, Vicente Baz, David, Artal, Angel, Amador, Mariluz, Provencio, Mariano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791371/
https://www.ncbi.nlm.nih.gov/pubmed/29382302
http://dx.doi.org/10.1186/s12885-018-4004-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791371/
https://www.ncbi.nlm.nih.gov/pubmed/29382302
http://dx.doi.org/10.1186/s12885-018-4004-7

Ejemplares similares